Precision medicine is one of the most talked about trends in healthcare. The promise is improved health outcomes and patient satisfaction, gained through an understanding of individual variability in genes, environment, and lifestyle. Recent commentators suggest that many of the technologies required to realize this goal already exist—and predict much wider application can be achieved by 2030.
At the heart of a precision medicine approach is data—huge amounts of data.
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
Precision medicine is poised to transform healthcare, with biobanks being identified as a key enabler to bring it to fruition by 2030 by putting new, extended datasets at the disposal of pharmaceutical researchers and healthcare professionals. — by Marilyn Matz
25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified
